{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:17:28Z","timestamp":1791357448960,"version":"4.3.1"},"update-to":[{"DOI":"10.1002\/14651858.cd006369","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2008,4,23]],"date-time":"2008-04-23T00:00:00Z","timestamp":1208908800000}}],"reference-count":146,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006369.pub2","type":"journal-article","created":{"date-parts":[[2008,4,21]],"date-time":"2008-04-21T09:56:47Z","timestamp":1208771807000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Oral paliperidone for schizophrenia"],"prefix":"10.1002","volume":"2012","author":[{"given":"Abraham M","family":"Nussbaum","sequence":"first","affiliation":[{"name":"Denver Health; Behavioral Health Service; MC 0490 777 Bannock Street Denver CO USA 80204"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T S","family":"Stroup","sequence":"additional","affiliation":[{"name":"Columbia University; Psychiatry; 1051 Riverside Drive Room 2703, Box 100 New York New York USA 10032"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,4,23]]},"reference":[{"key":"10.1002\/14651858.CD006369.pub2-BIB0001|cit1","doi-asserted-by":"crossref","unstructured":"Canuso C Carothers J Dirks B Zhu Y Kosik-Gonzalez C A double-blind placebo-controlled trial comparing paliperidone ER and quetiapine in patients with a recent acute exacerbation of schizophrenia Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-6; Washington DC Washington, DC 2008","DOI":"10.1016\/S0920-9964(08)70760-6"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006369.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S0920-9964(08)70760-6","article-title":"A double-blind placebo-controlled trial comparing paliperidone er and quetiapine in patients with a recent acute exacerbation of schizophrenia","volume":"102","author":"Canuso","year":"2008","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0003|cit3","unstructured":"Canuso C Dirks B Carothers J Zhu T Kosik-Gonzalez C A double-blind, placebo-controlled trial of paliperidone er and quetiapine in patients with a recent acute exacerbation of schizophrenia Proceedings of the 20th Annual U.S. Psychiatric & Mental Health Congress; 2007 11-14 Oct; Orlando, Florida Orlando, Florida 2007"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.schres.2007.12.372","article-title":"A comparative analysis of paliperidone er and quetiapine in patients with a recent, acute exacerbation of schizophrenia","volume":"98","author":"Canuso","year":"2008","journal-title":"Schizophrenia Research"},{"issue":"6","key":"10.1002\/14651858.CD006369.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1176\/appi.ajp.2009.08040613","article-title":"Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia","volume":"116","author":"Canuso","year":"2009","journal-title":"American Journal of Psychiatry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006369.pub2-BIB0006|cit6","first-page":"S62","article-title":"Evaluation of the pharmacokinetics of an extended-release formulation of paliperidone with an immediate-release formulation of risperidone","volume":"81","author":"Cleton","year":"2007","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006369.pub2-BIB0007|cit7","first-page":"S61","article-title":"Comparison of pharmacodynamic parameters resulting from administration of an paliperidone extended-release tablet formulation and an immediate-release formulation of risperidone in subjects with schizophrenia","volume":"81","author":"Cleton","year":"2007","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0008|cit8","unstructured":"Eerdekens M Kramer M Rossenu S Pandina G Boom S Francetic I Janssens L Cleton A Effect of paliperidone extended-release tablets on prolactin exposure in patients with stable schizophrenia (Poster no. 335) Proceedings of the USP and MHC; 2006 16-19 Nov; New Orleans, USA New Orleans, USA 2006"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0010|cit9","unstructured":"Davidson M Emsley R Kramer M Ford L Efficacy, safety and effect on functioning of paliperidone extended-release tablets in schizophrenia: an international 6-week placebo-controlled study Proceedings of the 13th Biennial Winter Workshop on Schizophrenia; 2006 Feb 4-10; Davos, Switzerland 2006"},{"issue":"1-3","key":"10.1002\/14651858.CD006369.pub2-BIB0009|cit10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.schres.2007.03.003","article-title":"Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study","volume":"93","author":"Davidson","year":"2007","journal-title":"Schizophrenia Research"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006369.pub2-BIB0011|cit11","first-page":"43","article-title":"Efficacy, safety and effect on functioning of oral paliperidone extended-release tablets in the acute treatment of schizophrenia: an international 6-week placebo-controlled study","volume":"81","author":"Davidson","year":"2006","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0012|cit12","unstructured":"Janssen-Cilag Ltd Data on File PCDoF2 Communication from Janssen-Cilag Ltd"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0013|cit13","unstructured":"Janssen-Cilag Ltd Data on File PCDoF2 Communication from Janssen-Cilag Ltd"},{"issue":"3","key":"10.1002\/14651858.CD006369.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.schres.2006.09.012","article-title":"Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo -controlled trial","volume":"90","author":"Kane","year":"2007","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0015|cit15","unstructured":"Kane J Kramer M Ford L Gassmann-Mayer C Lim P Eerdekens M Patients with acute schizophrenia: treatment with three fixed dosages of oral paliperidone extended-release tablets in an international 6-week placebo-controlled study Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada 2006"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0016|cit16","unstructured":"Kane J Kramer M Ford L Gassmann-Mayer C Lim P Eerdekens M Treatment of schizophrenia using oral paliperidone extended-release tablets: a 6-week placebo-controlled study Proceedings of the 13th Biennial Winter Workshop on Schizophrenia; 2006 Feb 4-10; Davos, Switzerland 2006"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006369.pub2-BIB0017|cit17","first-page":"s386","article-title":"Delaying symptom recurrence in patients with schizophrenia treated with paliperidone extended-release tablets","volume":"16","author":"Kramer","year":"2006","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD006369.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/JCP.0b013e31802dda4a","article-title":"Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"27","author":"Kramer","year":"2007","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD006369.pub2-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/YIC.0b013e3281c55f4f","article-title":"A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia","volume":"22","author":"Luthringer","year":"2007","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0020|cit20","unstructured":"Janssen-Cilag Ltd Data on File PCDoF2 Communication from Janssen-Cilag Ltd"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0022|cit21","unstructured":"Marder S Kramer M Ford L Eerdekens E Lim P Eerdekens M A 6-week, US-based placebo-controlled study on the efficacy and tolerability of two fixed dosages of oral paliperidone extended-release tablets in the treatment of acute schizophrenia Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada 2006"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006369.pub2-BIB0023|cit22","first-page":"56","article-title":"A 6-week, US-based placebo-controlled study on the efficacy and tolerability of two fixed dosages of oral paliperidone extended-release tablets in the treatment of acute schizophrenia","volume":"81","author":"Marder","year":"2006","journal-title":"Schizophrenia Research"},{"issue":"12","key":"10.1002\/14651858.CD006369.pub2-BIB0021|cit23","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.biopsych.2007.01.017","article-title":"Efficacy and safety of paliperidone extended-release tablets: results of a six-week, randomized, placebo-controlled study","volume":"62","author":"Marder","year":"2007","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0024|cit24","unstructured":"Tzimos A Kramer M Ford L Gassmann-Mayer C Lim P Eerdekens M A 6-week placebo-controlled study of the safety and tolerability of flexible doses of oral paliperidone extended-release tablets in the treatment of schizophrenia in elderly patients Proceedings of the 25th Collegium Internationale Neuro-psychopharmacologicum; 2006 Jul 9-13; Chicago, Illinois 2006"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0025|cit25","unstructured":"Tzimos A Kramer M Ford L Gassmann-Mayer C Lim P Eerdekens M A 6-week placebo-controlled study on the safety and tolerability of flexible doses of oral paliperidone extended-release tablets in the treatment of schizophrenia in elderly patients Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada 2006"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006369.pub2-BIB0026|cit26","first-page":"s464","article-title":"A 6-week placebo-controlled study of the safety and tolerability of flexible doses of oral paliperidone extended-release tablets in the treatment of schizophrenia in elderly patients","volume":"33","author":"Tzimos","year":"2007","journal-title":"Schizophrenia Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD006369.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/JGP.0b013e31815a3e7a","article-title":"Safety and Tolerability of Oral Paliperidone Extended-Release Tablets in Elderly Patients With Schizophrenia: A Double-Blind, Placebo-Controlled Study With Six-Month Open-Label Extension","volume":"16","author":"Tzimos","year":"2008","journal-title":"American Journal of Geriatric Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD006369.pub2-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s00213-007-1029-z","article-title":"Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D(2) receptor occupancy in patients with schizophrenia","volume":"197","author":"Arakawa","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"10.1002\/14651858.CD006369.pub2-BIB0029|cit29","first-page":"193","article-title":"Pharmacokinetics of risperidone in chronic schizophrenic patients","volume":"30","author":"Borison","year":"1994","journal-title":"Psychopharmacology Bulletin"},{"issue":"2","key":"10.1002\/14651858.CD006369.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.clpt.2005.12.079","article-title":"No pharmacokinetic interaction between trimethoprim and paliperidone ER in healthy subjects","volume":"79","author":"Cleton","year":"2006","journal-title":"Clinical pharmacology and therapeutics"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006369.pub2-BIB0031|cit31","first-page":"S62","article-title":"Evaluation of the pharmacokinetics of paliperidone extended-release tablets in healthy elderly subjects","volume":"81","author":"Cleton","year":"2007","journal-title":"Clinical pharmacology and therapeutics"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0032|cit32","unstructured":"Armenteros J Risperidone treatment of adolescents with schizophrenia CRISP database"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.schres.2007.12.373","article-title":"Pharmacodynamics of paliperidone extended-release tablets and immediate-release risperidone in schizophrenia","volume":"98","author":"Rossenu","year":"2008","journal-title":"Schizophrenia Research"},{"issue":"7066","key":"10.1002\/14651858.CD006369.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0035|cit35","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2009.06.014","article-title":"Paliperidone for treatment of obsessive-compulsive resistant symptoms in schizophrenia: A case report","author":"Angelucci","year":"2009","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD006369.pub2-BIB0036|cit36","first-page":"333","article-title":"Molecule of the month. Paliperidone","volume":"20","author":"Anonymous","year":"2007","journal-title":"Drug News Perspective"},{"issue":"92","key":"10.1002\/14651858.CD006369.pub2-BIB0037|cit37","first-page":"236","article-title":"Paliperidone: new drug. Just a metabolite of risperidone, a neuroleptic soon off-patent","volume":"16","author":"Anonymous","year":"2007","journal-title":"Prescrire International"},{"issue":"2","key":"10.1002\/14651858.CD006369.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00213-007-1029-z","article-title":"Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia","volume":"197","author":"Arakawa","year":"2008","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD006369.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s002130050726","article-title":"Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxy-risperidone in the brain and other tissues of rat","volume":"139","author":"Aravagiri","year":"1998","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006369.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1055\/s-2007-979308","article-title":"Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by a high performance liquid chromatography with electrochemical detection","volume":"31","author":"Aravagiri","year":"1998","journal-title":"Pharmacopsychiatry"},{"issue":"6","key":"10.1002\/14651858.CD006369.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/1096-9888(200006)35:6<718::AID-JMS999>3.0.CO;2-O","article-title":"Simultaneous determination of risperidone and 9-hydroxyrisperidone in plasma by liquid chromatography\/electrospray tandem mass spectrometry","volume":"35","author":"Aravagiri","year":"2000","journal-title":"Journal of Mass Spectrometry"},{"issue":"4","key":"10.1002\/14651858.CD006369.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s00213-001-0933-x","article-title":"Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats","volume":"159","author":"Aravagiri","year":"2002","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD006369.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/00007691-200312000-00003","article-title":"Intra- and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone","volume":"25","author":"Aravagiri","year":"2003","journal-title":"Therapeutic Drug Monitoring"},{"issue":"10","key":"10.1002\/14651858.CD006369.pub2-BIB0044|cit44","first-page":"625","article-title":"Forty years of antipsychotic Drug research from haloperidol to paliperidone with Dr. Paul Janssen","volume":"57","author":"Awouters","year":"2007","journal-title":"Arzneimittelforschung"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"British Journal of Psychiatry"},{"issue":"7108","key":"10.1002\/14651858.CD006369.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD006369.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1592\/phco.29.1.64","article-title":"Antipsychotic-induced hyperprolactinemia","volume":"29","author":"Bostwick","year":"2009","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.1002\/14651858.CD006369.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/jcp.0b013e31815ac4e5","article-title":"Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: Recent developments and current perspectives","volume":"27","author":"Byerly","year":"2007","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD006369.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/YIC.0b013e3282fce651","article-title":"Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone","volume":"23","author":"Canuso","year":"2008","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0050|cit50","article-title":"Efficacy and safety of paliperidone extended-release in schizophrenia patients with prominent affective symptoms","author":"Canuso","year":"2009","journal-title":"Journal of Affective Disorders"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0051|cit51","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2009.05.021","article-title":"Paliperidone extended-release for schizophrenia: Effects on symptoms and functioning in acutely ill patients with negative symptoms","author":"Canuso","year":"2009","journal-title":"Schizophrenia Research"},{"issue":"4","key":"10.1002\/14651858.CD006369.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1742-1241.2007.01321.x","article-title":"Paliperidone: quo vadis?","volume":"61","author":"Citrome","year":"2007","journal-title":"International Journal of Clinical Practice"},{"issue":"11","key":"10.1002\/14651858.CD006369.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"939","DOI":"10.2165\/00023210-200822110-00004","article-title":"Sleep disturbances in patients with schizophrenia : Impact and effect of antipsychotics","volume":"22","author":"Cohrs","year":"2008","journal-title":"CNS Drugs"},{"issue":"1-2","key":"10.1002\/14651858.CD006369.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.chroma.2008.10.094","article-title":"Study of the complexation of risperidone and 9-hydroxyrisperidone with cyclodextrin hosts using affinity capillary electrophoresis and (1)H NMR spectroscopy","volume":"1215","author":"Danel","year":"2008","journal-title":"Journal of chromatography"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0055|cit55","unstructured":"Deeks JJ Higgins JPT Altman DG Analysing and presenting results. Section 8: The Cochrane Library In Deeks JJ, Higgins JPT, Altman DG (editors). Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 [updated September 2008] The Cochrane Collaboration 2008"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0056|cit56","unstructured":"Dirks B Canuso C Eerdekens M Turkoz I Alberio R Gharabawi G Efficacy of paliperidone extended-release tablets in patients with schizophrenia and predominant negative symptoms International Journal of Neuropsychopharmacology 2006 162 10.1017\/S1461145706007292"},{"issue":"6","key":"10.1002\/14651858.CD006369.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"issue":"14","key":"10.1002\/14651858.CD006369.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1517\/14656566.8.14.2307","article-title":"Paliperidone: a new extended-release oral atypical antipsychotic","volume":"8","author":"Dlugosz","year":"2007","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"5","key":"10.1002\/14651858.CD006369.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2146\/ajhp070261","article-title":"Paliperidone for schizophrenia","volume":"65","author":"Dolder","year":"2008","journal-title":"American Journal of Health-System Pharmacy"},{"issue":"19","key":"10.1002\/14651858.CD006369.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006369.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2146\/ajhp070505","article-title":"Paliperidone: an improvement over risperidone?","volume":"65","author":"Dopheide","year":"2008","journal-title":"American Journal of Health-System Pharmacy"},{"issue":"4","key":"10.1002\/14651858.CD006369.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1176\/jnp.2007.19.4.477","article-title":"Possible neuroleptic malignant syndrome associated with paliperidone","volume":"19","author":"Duggal","year":"2007","journal-title":"Journal of Neuropsychiatry Clinical Neuroscience"},{"issue":"2","key":"10.1002\/14651858.CD006369.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.psyneuen.2007.10.010","article-title":"Relationship between prolactin secretion, and plasma risperidone and 9-hydroxyrisperidone concentrations in adolescents with schizophreniform disorder","volume":"33","author":"Duval","year":"2008","journal-title":"Psychoneuroendocrinology"},{"issue":"12","key":"10.1002\/14651858.CD006369.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1185\/03007990802490512","article-title":"One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia","volume":"24","author":"Edwards","year":"2008","journal-title":"Current Medical Research Opinion"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"13","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD006369.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials:methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"6","key":"10.1002\/14651858.CD006369.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/YIC.0b013e328314e1f3","article-title":"Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled ate from three 52-week open-label studies","volume":"23","author":"Emsley","year":"2008","journal-title":"International Clinical Psychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD006369.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1365-2125.2008.03276.x","article-title":"Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study","volume":"66","author":"Feng","year":"2008","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006369.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/0269216307087148","article-title":"Prolactin and dopamine: what is the connection? A review article","volume":"22","author":"Fitzgerald","year":"2008","journal-title":"Journal of Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD006369.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.clinthera.2008.02.011","article-title":"Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia","volume":"30","author":"Fowler","year":"2008","journal-title":"Clinical Therapeutics"},{"issue":"18","key":"10.1002\/14651858.CD006369.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMra035458","article-title":"Schizophrenia","volume":"349","author":"Freedman","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD006369.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1365-2230.2008.02954.x","article-title":"Secondary delusional parasitosis treated with paliperidone","volume":"34","author":"Freudenmann","year":"2009","journal-title":"Clinical and Experimental Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD006369.pub2-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/clpt.2008.234","article-title":"An agonist-antagonist interaction model for prolactin release following risperidone and paliperidone treatment","volume":"85","author":"Friberg","year":"2009","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006369.pub2-BIB0074|cit74","first-page":"288","article-title":"Reliability, validity and sensitivity to change of the personal and social performance scale in patients with stable schizophrenia","volume":"9","author":"Gagnon","year":"2006","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1744-859X-7-16","article-title":"Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: A cost effectiveness study","volume":"7","author":"Geitona","year":"2008","journal-title":"Annals of General Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD006369.pub2-BIB0076|cit76","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002306","article-title":"Risperidone versus other atypical antipsychotic medication for schizophrenia","author":"Gilbody","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD006369.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/JCP.0b013e3181befa2a","article-title":"Onset and persistence of antipsychotic response in patients with schizophrenia","volume":"29","author":"Glick","year":"2009","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"9","key":"10.1002\/14651858.CD006369.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0079|cit79","volume-title":"Early clinical drug evaluation (ECDEU) assessment manual for psychopharmacology","author":"Guy","year":"1976"},{"issue":"3","key":"10.1002\/14651858.CD006369.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/schbul\/10.3.388","article-title":"The quality of life scale: an instrument for rating the schizophrenic deficit syndrome","volume":"10","author":"Heinrichs","year":"1984","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0081|cit81","doi-asserted-by":"crossref","unstructured":"Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 [updated September 2008] The Cochrane Collaboration 2008","DOI":"10.1002\/9780470712184"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/archpsyc.1974.01760170005001","article-title":"Drug and sociotherapy in the aftercare of schizophrenic patients: two-year relapse rates","volume":"31","author":"Hogarty","year":"1974","journal-title":"Archives of General Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD006369.pub2-BIB0083|cit83","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004161","article-title":"Depot risperidone for schizophrenia","author":"Hosalli","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD006369.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/JCP.0b013e3181b5f40b","article-title":"Independent effect of paliperidone extended release on social functioning beyond its effect on positive and negative symptoms of schizophrenia: a mediation analysis","volume":"29","author":"Hough","year":"2009","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD006369.pub2-BIB0085|cit85","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000440","article-title":"Risperidone versus typical antipsychotic medication for schizophrenia","author":"Hunter","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD006369.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"276","DOI":"10.4140\/TCP.n.2008.276","article-title":"New drug update: 2007","volume":"23","author":"Hussar","year":"2008","journal-title":"The Consultant Pharmacist"},{"issue":"5","key":"10.1002\/14651858.CD006369.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1055\/s-2008-1078747","article-title":"Choreatic symptoms during and after treatment with paliperidone and escitalopram","volume":"41","author":"Huther","year":"2008","journal-title":"Pharmacopsychiatry"},{"issue":"2","key":"10.1002\/14651858.CD006369.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1345\/aph.1D326","article-title":"Transfer of risperidone and 9-hydroxyrisperidone into human milk","volume":"38","author":"Illett","year":"2004","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0089|cit89","volume-title":"Principles and Practice of Psychopharmacology","author":"Janicak","year":"2006"},{"issue":"6","key":"10.1002\/14651858.CD006369.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1185\/03007990802119368","article-title":"Hospitalization rates before and after initiation of paliperidone ER in patients with schizophrenia: results from open-label extensions of the US double-blind trials","volume":"24","author":"Janicak","year":"2008","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0091|cit91","unstructured":"Janicak PG Jasmanda HW Amatniek J Mao L Pesa J Trott J Kozma C Canuso CM Changes in mental health resource use after initiation of paliperidone ER in patients with schizophrenia Proceedings of the Institute of Psychiatrics Services Annual Meeting; 2008 Oct 2-5; Chicago Chicago 2008"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0092|cit92","unstructured":"Janssen Pharmaceutica Products LP Risperdal Consta (risperidone) long-acting injection prescribing information Janssen Pharmaceutica Products, L.P. 2003"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0093|cit93","unstructured":"Janssen Pharmaceutica Products LP Invega (paliperidone) extended-release tablets prescribing information Janssen Pharmaceutica Products, L.P. 2006"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0094|cit94","unstructured":"Janssen-Cilag Ltd Risperidal (risperidone) summary of product characteristics UK: Janssen-Cilag Ltd 1996"},{"issue":"2","key":"10.1002\/14651858.CD006369.pub2-BIB0095|cit95","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005237.pub2","article-title":"Risperidone versus olanzapine for schizophrenia","author":"Jayaram","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD006369.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/j.1365-2850.2008.01299.x","article-title":"What are the nursing implications when using paliperidone prolonged release for people with schizophrenia","volume":"15","author":"Jones","year":"2008","journal-title":"Journal of Psychiatric and Mental Health Nursing"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0097|cit97","unstructured":"Jones MP Nicholl D Trakas K Efficacy-tolerability profiles of oral atypical antipsychotics for schizophrenia: a meta-analysis including paliperidone extended-release Proceedings of the 11th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR); 2008 Nov 8-11; Athens, Greece Athens, Greece 2008"},{"issue":"10","key":"10.1002\/14651858.CD006369.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0024-3205(95)02037-J","article-title":"The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study","volume":"57","author":"Kapur","year":"1995","journal-title":"Life Science"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006369.pub2-BIB0099|cit99","first-page":"85","article-title":"Pharmacokinetics and dopamine D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects","volume":"81","author":"Karlsson","year":"2006","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0100|cit100","volume-title":"The positive and negative syndrome scale (PANSS) manual","author":"Kay","year":"1986"},{"issue":"5","key":"10.1002\/14651858.CD006369.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1176\/appi.ajp.162.5.1010","article-title":"Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels","volume":"162","author":"Knegtering","year":"2005","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD006369.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1124\/mol.108.052084","article-title":"Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-Hydroxytryptamine7 receptor by risperidone, 9-OH-Risperidone, and other inactivating antagonists","volume":"75","author":"Knight","year":"2009","journal-title":"Molecular Pharmacology"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0103|cit103","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1017\/S1461145706007292","article-title":"Paliperidone extended-release tablets in patients recently diagnosed with schizophrenia","volume":"9","author":"Kostic","year":"2006","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.schres.2007.12.408","article-title":"Oral paliperidone extended-release treatment: long-term metabolic outcomes in patients with schizophrenia","volume":"98","author":"Kramer","year":"2008","journal-title":"Schizophrenia Research"},{"issue":"2","key":"10.1002\/14651858.CD006369.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1586\/14737175.8.2.193","article-title":"Paliperidone-ER: first atypical antipsychotic with oral extended release formulation","volume":"8","author":"Lautenschlager","year":"2008","journal-title":"Expert Review of Neurotherapeutics"},{"issue":"3","key":"10.1002\/14651858.CD006369.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1055\/s-2007-973836","article-title":"A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels","volume":"40","author":"Leon","year":"2007","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of Brief Psychiatric Rating Scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"The British Journal of Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD006369.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia research"},{"issue":"12","key":"10.1002\/14651858.CD006369.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0110|cit110","volume-title":"The American Psychiatric Publishing Textbook of Schizophrenia","author":"Lieberman","year":"2006"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/(SICI)1099-1077(199808)13:6<413::AID-HUP12>3.0.CO;2-A","article-title":"The safety of risperidone: a post-marketing study on 7684 patients","volume":"13","author":"Mackay","year":"1998","journal-title":"Human Psychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD006369.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0090-9556(25)08211-X","article-title":"Absorption, metabolism, and excretion of risperidone in humans","volume":"21","author":"Mannens","year":"1993","journal-title":"Drug Metabolism and Disposition"},{"issue":"12","key":"10.1002\/14651858.CD006369.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4088\/JCP.v58n1205","article-title":"The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trials","volume":"58","author":"Marder","year":"1997","journal-title":"Journal of Clinical Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD006369.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1592\/phco.28.10.1283","article-title":"Paliperidone extended-release for the treatment of schizophrenia","volume":"28","author":"Marino","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD006369.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/hup.811","article-title":"Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite","volume":"21","author":"Melkersson","year":"2006","journal-title":"Human Psychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD006369.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"817","DOI":"10.4088\/JCP.v69n0515","article-title":"Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies","volume":"69","author":"Meltzer","year":"2008","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials","volume":"285","author":"Moher","year":"2001","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD006369.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/sj.mp.4002066","article-title":"Atypical antipsychotic-induced metabolic side effects: insight from receptor-binding profiles","volume":"13","author":"Nasrallah","year":"2008","journal-title":"Molecular Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD006369.pub2-BIB0120|cit120","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006369.pub2","article-title":"Paliperidone for schizophrenia","author":"Nussbaum","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"issue":"5","key":"10.1002\/14651858.CD006369.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/hup.850","article-title":"Limitations in discerning the effects of risperidone and its 9-hydroxy metabolite on prolactin levels in a small study of patients with schizophrenia","volume":"22","author":"Pandina","year":"2007","journal-title":"Human Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006369.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1517\/17425240902780158","article-title":"Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release","volume":"6","author":"Pani","year":"2009","journal-title":"Expert Opinion On Drug Delivery"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006369.pub2-BIB0124|cit124","first-page":"S287","article-title":"Reliability, validity and sensitivity to change of the personal and social performance scale in patients with acute schizophrenia","volume":"9","author":"Patrick","year":"2006","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD006369.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1185\/03007990802611919","article-title":"Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia","volume":"25","author":"Patrick","year":"2009","journal-title":"Current Medical Research and Opinion"},{"issue":"6","key":"10.1002\/14651858.CD006369.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1097\/JCP.0b013e31818d7ca2","article-title":"The disparity of pharmacokinetics and prolactin study for risperidone long-acting injection","volume":"28","author":"Peng","year":"2008","journal-title":"Journal of clinical psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006369.pub2-BIB0127|cit127","first-page":"396","article-title":"Paliperidon mediated modification of cortical inhibition","volume":"30","author":"P\u0159ikryl","year":"2009","journal-title":"Neuro Endocrinol Lett"},{"issue":"9","key":"10.1002\/14651858.CD006369.pub2-BIB0128|cit128","first-page":"75","article-title":"Paliperidone ER: Reformulated antipsychotic for schizophrenia Tx","volume":"6","author":"Rado","year":"2007","journal-title":"Current Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD006369.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1055\/s-0028-1102913","article-title":"Paliperidone in an adult patient with asperger syndrome: case report","volume":"42","author":"Roser","year":"2009","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0130|cit130","volume-title":"Modern Psychometrics","author":"Rust","year":"1989"},{"issue":"22","key":"10.1002\/14651858.CD006369.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.2146\/ajhp070615","article-title":"Apparent seizure and atrial fibrillation associated with paliperidone","volume":"65","author":"Schneider","year":"2008","journal-title":"American Journal of Health-System Pharmacy"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0132|cit132","unstructured":"Schooler N Bossie C Canuso C Turkoz I Lindenmayer JP A \"virtual\" comparison of paliperidone er and risperidone ir in patients with schizophrenia Proceedings of the International Congress on Schizophrenia Research; 2007 Mar 28-1; Colorado Springs, Colorado Colorado Springs, Colorado 2007"},{"issue":"4","key":"10.1002\/14651858.CD006369.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00213-008-1412-4","article-title":"Paliperidone suppresses the development of the aggressive phenotype in a developmentally sensitive animal model of escalated aggression","volume":"203","author":"Schwartzer","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"issue":"11","key":"10.1002\/14651858.CD006369.pub2-BIB0134|cit134","first-page":"118","article-title":"Paliperidone: long-acting antipsychotic can be taken once daily","volume":"5","author":"Simpson","year":"2006","journal-title":"Current Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD006369.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"426","DOI":"10.2165\/00023210-200721050-00006","article-title":"Paliperidone Extended Release","volume":"21","author":"Simpson","year":"2007","journal-title":"CNS Drugs"},{"issue":"6","key":"10.1002\/14651858.CD006369.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1517\/14740338.6.6.651","article-title":"The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia","volume":"6","author":"Spina","year":"2007","journal-title":"Expert Opinion Drug Safety"},{"issue":"5","key":"10.1002\/14651858.CD006369.pub2-BIB0137|cit137","first-page":"949","article-title":"Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia","volume":"4","author":"Turkoz","year":"2008","journal-title":"Neuropsychiatric disease and treatment"},{"issue":"5","key":"10.1002\/14651858.CD006369.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"issue":"5","key":"10.1002\/14651858.CD006369.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2174\/138920008784746373","article-title":"Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions","volume":"9","author":"Urichuk","year":"2008","journal-title":"Current drug metabolism"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006369.pub2-BIB0140|cit140","first-page":"S648","article-title":"Absorption, metabolism and excretion of a single oral dose of 14C-paliperidone 1 mg in healthy subjects","volume":"15","author":"Vermeir","year":"2005","journal-title":"European Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD006369.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1124\/dmd.107.018275","article-title":"Absorption, Metabolism, and Excretion of Paliperidone, a New Monoaminergic Antagonist, in Humans","volume":"36","author":"Vermeir","year":"2008","journal-title":"Drug metabolism and Disposition"},{"issue":"2","key":"10.1002\/14651858.CD006369.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10928-006-9040-2","article-title":"Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar disorder","volume":"34","author":"Vermeulen","year":"2007","journal-title":"Journal of Pharmacokinetics and Pharmacodynamics"},{"issue":"9","key":"10.1002\/14651858.CD006369.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/0269881107077357","article-title":"Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia","volume":"21","author":"Wang","year":"2007","journal-title":"Journal of Psychopharmacology"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1192\/bjp.177.1.42","article-title":"Self-report quality of life measure for people with schizophrenia: the SQLS","volume":"177","author":"Wilkinson","year":"2000","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006369.pub2-BIB0145|cit145","unstructured":"Xia J Adams CE Bhagat N Bhagat V Bhoopathi P El-Sayeh H Pinfold V Takriti Y The Leeds Outcomes Stakeholders Survey (LOSS) Study Proceedings of the 15th Cochrane Colloquium; 2007 Oct 23-27; Sao Paulo 2007"},{"issue":"5","key":"10.1002\/14651858.CD006369.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2165\/00023210-200721050-00005","article-title":"Paliperidone extended release","volume":"21","author":"Yang","year":"2007","journal-title":"CNS Drugs"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD006369.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T10:02:45Z","timestamp":1749636165000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006369.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2008,4,23]]},"references-count":146,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2012,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006369.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,23]]}}}